[1] Pauwels, R.A. and Rabe, K.F. (2004) Burden and Clinical Features of Chronic Obstructive Pulmonary Disease (COPD). Lancet, 364, 613-620.
http://dx.doi.org/10.1016/S0140-6736(04)16855-4
[2] Brody, H. (2012) Chronic Obstructive Pulmonary Disease. Nature, 489, S1.
http://dx.doi.org/10.1038/489S1a
[3] MacIntyre, N. and Huang, Y.C. (2008) Acute Exacerbations and Respiratory Failure in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 5, 530-535.
http://dx.doi.org/10.1513/pats.200707-088ET
[4] Garcia-Olmos, L., Alberquilla, A., Ayala, V., et al. (2013) Comorbidity in Patients with Chronic Obstructive Pulmonary Disease in Family Practice: A Cross Sectional Study. BMC Family Practice, 14, 11.
http://dx.doi.org/10.1186/1471-2296-14-11
[5] Celli, B.R., Thomas, N.E., Anderson, J.A., et al. (2008) Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study. American Journal of Respiratory and Critical Care Medicine, 178, 332-338.
http://dx.doi.org/10.1164/rccm.200712-1869OC
[6] Rana, J.S., Mittleman, M.A., Sheikh, J., et al. (2004) Chronic Obstructive Pulmonary Disease, Asthma, and Risk of Type 2 Diabetes in Women. Diabetes Care, 27, 2478-2484.
http://dx.doi.org/10.2337/diacare.27.10.2478
[7] Neukamm, A., Hoiseth, A.D., Einvik, G., et al. (2015) Rosuvastatin Treatment in Stable Chronic Obstructive Pulmonary Disease (RODEO): A Randomized Controlled Trial. Journal of Internal Medicine, 278, 59-67.
http://dx.doi.org/10.1111/joim.12337
[8] Horita, N., Miyazawa, N., Kojima, R., et al. (2014) Statins Reduce All-Cause Mortality in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Observational Studies. Respiratory Research, 15, 80.
[9] Suissa, S., Dell’Aniello, S. and Ernst, P. (2012) Long-Term Natural History of Chronic Obstructive Pulmonary Disease: Severe Exacerbations and Mortality. Thorax, 67, 957-963.
http://dx.doi.org/10.1136/thoraxjnl-2011-201518
[10] Chang, C., Zhu, H., Shen, N., et al. (2015) Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes before and after Treatment of AECOPD, a Longitudinal and Cross-Sectional Study. Copd, 12, 19-30.
http://dx.doi.org/10.3109/15412555.2014.898043
[11] Boorsma, C.E., Draijer, C. and Melgert, B.N. (2013) Macrophage Heterogeneity in Respiratory Diseases. Mediators of Inflammation, 2013, Article ID: 769214.
http://dx.doi.org/10.1155/2013/769214
[12] Barnes, P.J. (2013) New Anti-Inflammatory Targets for Chronic Obstructive Pulmonary Disease. Nature Reviews Drug Discovery, 12, 543-559.
http://dx.doi.org/10.1038/nrd4025
[13] Chawla, A., Nguyen, K.D. and Goh, Y.P. (2011) Macrophage-Mediated Inflammation in Metabolic Disease. Nature Reviews Immunology, 11, 738-749.
http://dx.doi.org/10.1038/nri3071
[14] Xu, H.Y., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., et al. (2003) Chronic Inflammation in Fat Plays a Crucial Role in the Development of Obesity-Related Insulin Resistance. The Journal of Clinical Investigation, 112, 1821-1830. http://dx.doi.org/10.1172/JCI200319451
[15] Lumeng, C.N., Bodzin, J.L. and Saltiel, A.R. (2007) Obesity Induces a Phenotypic Switch in Adipose Tissue Macrophage Polarization. The Journal of Clinical Investigation, 117, 175-184.
http://dx.doi.org/10.1172/JCI29881
[16] Zhao, L., Zhong, S., Qu, H.Y., Xie, Y.X., Cao, Z.N., Li, Q., et al. (2015) Chronic Inflammation Aggravates Metabolic Disorders of Hepatic Fatty Acids in High-Fat Diet-Induced Obese Mice. Scientific Reports, 5, Article No.: 10222.
http://dx.doi.org/10.1038/srep10222
[17] Pierce, K.L., Premont, R.T. and Lefkowitz, R.J. (2002) Seven-Transmembrane Receptors. Nature Reviews Molecular Cell Biology, 3, 639-650.
http://dx.doi.org/10.1038/nrm908
[18] Sprenger, J.U., Perera, R.K., Steinbrecher, J.H., Lehnart, S.E., Maier, L.S., Hasenfuss, G. and Nikolaev, V.O. (2015) In Vivo Model with Targeted cAMP Biosensor Reveals Changes in Receptor-Microdomain Communication in Cardiac Disease. Nature Communications, 6, Article No.: 6965.
http://dx.doi.org/10.1038/ncomms7965
[19] Jin, S.L., Lan, L., Zoudilova, M. and Conti, M. (2005) Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages. Journal of Immunology, 175, 1523-1531.
http://dx.doi.org/10.4049/jimmunol.175.3.1523
[20] Jin, S.L. and Conti, M. (2002) Induction of the Cyclic Nucleotide Phosphodiesterase PDE4B Is Essential for LPS-Activated TNF-Alpha Responses. Proceedings of the National Academy of Sciences of the United States of America, 99, 7628-7633.
http://dx.doi.org/10.1073/pnas.122041599
[21] Zhang, R., Maratos-Flier, E. and Flier, J.S. (2009) Reduced Adiposity and High-Fat Diet-Induced Adipose Inflammation in Mice Deficient for Phosphodiesterase 4B. Endocrinology, 150, 3076-3082.
http://dx.doi.org/10.1210/en.2009-0108
[22] Luan, B., Goodarzi, M.O., Phillips, N.G., Guo, X.Q., Chen, Y.-D.I., Yao, J., et al. (2014) Leptin-Mediated Increases in Catecholamine Signaling Reduce Adipose Tissue Inflammation via Activation of Macrophage HDAC4. Cell Metabolism, 19, 1058-1065.
http://dx.doi.org/10.1016/j.cmet.2014.03.024
[23] Vollert, S., Kaessner, N., Heuser, A., Hanauer, G., Dieckmann, A., Knaack, D., et al. (2012) The Glucose-Lowering Effects of the PDE4 Inhibitors Roflumilast and Roflumilast-N-Oxide in db/db Mice. Diabetologia, 55, 2779-2788.
http://dx.doi.org/10.1007/s00125-012-2632-z
[24] Yan, L., Park, J.Y., Dillinger, J.G., De Lorenzo, M.S., Yuan, C.J., Lai, L., et al. (2012) Common Mechanisms for Calorie Restriction and Adenylyl Cyclase Type 5 Knockout Models of Longevity. Aging Cell, 11, 1110-1120.
http://dx.doi.org/10.1111/acel.12013
[25] Jeon, B.T., Jeong, E.A., Shin, H.J., Lee, Y., Lee, D.H., Kim, H.J., et al. (2012) Resveratrol Attenuates Obesity-Asso- ciated Peripheral and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet. Diabetes, 61, 1444-1454.
http://dx.doi.org/10.2337/db11-1498
[26] Wouters, E.F., Bredenbroker, D., Teichmann, P., Brose, M., Rabe, K.F., Fabbri, L.M. and Goke, B. (2012) Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology and Metabolism, 97, E1720-E1725.
http://dx.doi.org/10.1210/jc.2011-2886
[27] Jensterle, M., Kocjan, T. and Janez, A. (2014) Phosphodiesterase 4 Inhibition as a Potential New Therapeutic Target in Obese Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism, 99, E1476-E1481.
http://dx.doi.org/10.1210/jc.2014-1430
[28] Fabbri, L.M., Beghe, B., Yasothan, U. and Kirkpatrick, P. (2010) Roflumilast. Nature Reviews Drug Discovery, 9, 761-762.
http://dx.doi.org/10.1038/nrd3276
[29] Buenestado, A., Chaumais, M.C., Grassin-Delyle, S., Risse, P.-A., Naline, E., Longchampt, E., et al. (2013) Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha and Chemokine Production by Human Lung Parenchyma. PLoS ONE, 8, e74640.
http://dx.doi.org/10.1371/journal.pone.0074640
[30] Martinez, F.J., Calverley, P.M., Goehring, U.M., Brose, M., Fabbri, L.M. and Rabe, K.F. (2015) Effect of Roflumilast on Exacerbations in Patients with Severe Chronic Obstructive Pulmonary Disease Uncontrolled by Combination Therapy (REACT): A Multicentre Randomised Controlled Trial. The Lancet, 385, 857-866.
http://dx.doi.org/10.1016/S0140-6736(14)62410-7